Clinical Research Directory
Browse clinical research sites, groups, and studies.
IL-15 Enhanced NK Cell Therapy for Solid Tumors
Sponsor: Genovn Therapeutics (Suzhou) Co., Ltd.
Summary
A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.
Official title: A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed/Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-07-01
Completion Date
2028-12-31
Last Updated
2026-06-02
Healthy Volunteers
No
Conditions
Interventions
IL-15 enhanced engineered NK cells
Genetically engineered NK cells expressing IL-15. Administered intravenously. See protocol for dose details.
IL-15 Enhanced Engineered NK Cells
Genetically engineered NK cells expressing IL-15
Locations (1)
Xinqiao Hospital
Chongqing, China